Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

ViiV Stops Development of NNRTI Lersivirine

March/April 2013

On 5 February 2013, in a letter to community organisations, ViiV Healthcare announced that it has stopped the development programme of the investigational NNRTI lersivirine.1

The letter states: "After much deliberation about how to proceed with lersivirine, it was determined that the compound would not provide an improvement over existing medicines in the NNRTI class, and that R&D resources for ViiV Healthcare should prioritize efforts to identify compounds that further HIV treatment. We remain committed to exploring candidates that will advance HIV treatment and contribute to improving outcomes for people living with HIV."

It continued: "Individuals currently enrolled in trials to investigate lersivirine will be switched to an alternative HIV treatment regimen upon study discontinuation. However, if there are individuals that are benefiting from lersivirine for whom an appropriate alternative treatment option cannot be prescribed, we will continue to offer lersivirine until such time that they are no longer deriving clinical benefit."

This coincided with the publication in JAIDS of 48-week results of a phase 2b study comparing lersivirine to efavirenz in treatment naive patients.2


References

  1. ViiV Healthcare. Update Status of Lersivirine Development Program. 5 February 2013.
  2. Vernazza et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. JAIDS. 62(2):171-179. Published online ahead of print. February 1, 2013. doi: 10.1097/QAI.0b013e31827a2ba2.

Links to other websites are current at date of posting but not maintained.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 
See Also
Lersivirine

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement